Core Points - Atos SE has completed a reverse stock split as decided by its Board of Directors on March 6, 2025, following a delegation of powers by the shareholders' General Meeting on January 31, 2025 [1][2][3] Summary by Sections Reverse Stock Split Details - The reverse stock split is a technical exchange transaction that does not affect the total value of shares held by shareholders [2] - The exchange ratio is 10,000 old shares with a par value of €0.0001 for 1 new share with a par value of €1 [9] - The total number of old shares subject to the reverse stock split was 190,358,728,519, resulting in 19,035,872 new shares [9] Shareholder Actions - Shareholders holding multiples of 10,000 shares do not need to take any action as their shares were automatically consolidated [4] - Shareholders with fractional rights will be compensated by their financial intermediaries within 30 days of April 24, 2025 [5] Adjustments Related to Warrants - The exercise parity of the share subscription warrants issued on December 18, 2024, has been adjusted in accordance with the reverse stock split [6][7] - The new exercise parity corresponds to the product of the previous exercise parity and the ratio of new shares to old shares, resulting in a maximum of 1,107,589 new ordinary shares available upon exercise [7] Adjustments for Free Share Allocations - The rights of beneficiaries of free share allocations have been adjusted to reflect the reverse stock split, with the number of rights allocated being rounded down to the nearest whole number if necessary [10][11] Trading and Timetable - The new shares began trading on Euronext Paris on April 24, 2025, under ISIN code FR001400X2S4 [9][12] - The compensation period for shareholders with fractional rights runs from April 24 to May 25, 2025 [12] Company Overview - Atos is a global leader in digital transformation with approximately 74,000 employees and annual revenue of around €10 billion [13] - The company specializes in cybersecurity, cloud, and high-performance computing, providing tailored solutions across 68 countries [13]

Core Points - Sharps Technology, Inc. will implement a 1-for-300 reverse stock split effective April 27, 2025, to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse split will reduce the authorized common shares from 500,000,000 to 1,666,667, and it was approved by the Board without shareholder consent [3] Company Overview - Sharps Technology is a medical device and pharmaceutical packaging company that specializes in patented smart-safety syringe products aimed at the healthcare industry [4] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [4] - Sharps also produces products designed with specialized copolymer technology for the prefillable syringe market segment and operates a manufacturing facility in Hungary [4]

RONKONKOMA, N.Y., April 16, 2025 (GLOBE NEWSWIRE) -- SUNation Energy, Inc. (Nasdaq: SUNE) (“SUNation” or “the Company”), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that its Board of Directors approved a 200 - for 1 reverse stock split of the Company’s outstanding common stock effective 12:01 a.m. Eastern Time on April 21, 2025. The Company’s common stock will continue to trade under the symbol “SUNE” and it is exp ...

Core Points - Cara Therapeutics, Inc. has announced a 1-for-3 reverse stock split of its outstanding shares of common stock [1] - The company's common stock will begin trading under the new name "Tvardi Therapeutics, Inc." and the new symbol "TVRD" following the merger with Tvard Therapeutics, Inc. [2] - The reverse stock split was approved by stockholders and will reduce the number of outstanding shares from approximately 4.6 million to approximately 1.5 million [3][4] Company Overview - Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases [7] - Cara Therapeutics is a biopharmaceutical company that has developed an IV formulation of difelikefalin for treating moderate-to-severe pruritus associated with advanced kidney disease [8]

Core Viewpoint - Antelope Enterprise Holdings Limited will implement a 1-for-40 reverse stock split of its Class A ordinary shares effective April 4, 2025, to comply with NASDAQ's minimum bid price requirement of $1.00 per share [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will consolidate every 40 issued and outstanding Ordinary Shares into one Ordinary Share, reducing the total number of shares from approximately 41,430,051 to about 1,035,752 [3]. - Shareholders entitled to fractional shares will receive one full share instead of a fractional share [3]. - All outstanding stock options, warrants, and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately due to the reverse stock split [3]. Group 2: Compliance and Listing Requirements - The reverse stock split is aimed at regaining compliance with NASDAQ's requirement that the Company's common stock must have a closing bid price of $1.00 or more for at least ten consecutive trading days by April 30, 2025 [2]. - There is uncertainty regarding whether the Ordinary Shares will remain above the $1.00 minimum bid price after the reverse split, which is crucial for maintaining NASDAQ listing compliance [2]. Group 3: Company Overview - Antelope Enterprise holds a 51% ownership stake in Hainan Kylin Cloud Services Technology Co. Ltd, which operates a livestreaming e-commerce business in China, providing access to over 800,000 hosts and influencers [5].

Core Viewpoint - MarketWise, Inc. will implement a 1-for-20 reverse stock split to enhance its stock price and meet Nasdaq listing requirements, effective April 2, 2025 [1][6]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding Class A common stock from approximately 49,487,262 shares to about 2,474,363 shares, and Class B common stock from approximately 276,623,803 shares to about 13,831,190 shares [3]. - The authorized Class A common stock will decrease from 950,000,000 shares to 47,500,000 shares, and Class B common stock from 300,000,000 shares to 15,000,000 shares [5]. - Fractional shares resulting from the reverse stock split will be paid in cash based on the closing price on April 2, 2025 [6]. Group 2: Rationale and Expectations - The reverse stock split aims to bring the stock price into a range more aligned with the company's market capitalization, making it more appealing to institutional investors and improving market perception [3]. - The company believes that the higher share price will help meet Nasdaq's minimum bid price requirement of $1.00 per share [6]. Group 3: Company Overview - MarketWise is a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors [7]. - The company has over 25 years of operating history and serves millions of subscribers, offering its products through various digital platforms [8].